Keryx Biopharmaceuticals (KERX) 11.63 $KERX
Downtrend Call Working As Keryx Biopharmaceuticals Stock Falls 25.7% (KERX)
Comtex SmarTrend(R) - Mon Feb 09, 9:44AM CST
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on December 12th, 2014 at $14.65. In approximately 2 months, Keryx Biopharmaceuticals has returned 25.73% as of today's recent price of $10.88.
KERX: 11.63 (-0.60)
Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch
at The Street - Mon Feb 09, 7:36AM CST
Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.
KERX: 11.63 (-0.60)
Why Keryx Biopharmaceuticals Shares Plummeted 14% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 8:55AM CST
KERX data by YCharts What: Shares of Keryx Biopharmaceuticals , a biopharmaceutical company focused on developing treatments for renal diseases, plummeted 14% in January per data from S&P Capital IQ following a share issuance and a...
KERX: 11.63 (-0.60)
Shares of KERX Down 17.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 02, 9:25AM CST
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on December 12th, 2014 at $14.65. In approximately 2 months, Keryx Biopharmaceuticals has returned 17.34% as of today's recent price of $12.11.
KERX: 11.63 (-0.60)
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 3:10PM CST
Keryx (KERX) will be raising $110 million through the issuance of the shares with plans to invest the funds on the ongoing commercialization and development of Auryxia in the U.S.
ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30), KERX: 11.63 (-0.60), CELG: 115.88 (+0.16)
Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 7:31AM CST
Keryx Biopharmaceuticals saw a big move last session, as the company’s shares fell by nearly 7% on the day.
ALXN: 182.29 (+6.02), KERX: 11.63 (-0.60)
Keryx prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:27AM CST
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
GlobeNewswire - Wed Jan 21, 6:53PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares at $12.00 per share, for gross proceeds of $110 million. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia(TM) (ferric citrate) in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
JPM: 59.67 (+0.10), KERX: 11.63 (-0.60)
Keryx initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 3:11PM CST
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jan 20, 3:06PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that it has commenced a $100 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
JPM: 59.67 (+0.10), KERX: 11.63 (-0.60)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Dyadic Appoints Michael Tarnok As Chairman Of The Board Of Directors
PR Newswire - Mon Jan 12, 7:40AM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok as the company's Chairman of the Board of Directors. Mr. Tarnok will continue to serve on the company's audit and compensation committees.
KERX: 11.63 (-0.60)
New chief at Keryx
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:36PM CST
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals Announces Transition of Leadership
GlobeNewswire - Sun Jan 11, 9:00PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company" today announced it will be transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison. Mr. Bentsur has led Keryx for the past 5 years, culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia(TM) (ferric citrate). Mr. Madison joined Keryx in February 2014 as Chief Operating Officer to transition the Company from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the phosphate binder and iron deficiency anemia markets. Mr. Madison has been appointed President of Keryx and will work with Mr. Bentsur to ensure a successful leadership transition by the end of May, when Mr. Bentsur's contract expires.
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
Business Wire - Thu Jan 08, 6:01AM CST
In 2014, Keryx Biopharmaceuticals needed to quickly build a commercial foundation for product sales and marketing to support its first FDA-approved product, Auryxia(TM) (ferric citrate). Keryx required a best-of-breed solution that would enable business agility and continuous improvement, plus easily accommodate change and rapid growth. Keryx found it in Veeva Commercial Cloud - a single solution that brings together customer data, multichannel interactions, and compliant content for a fully orchestrated customer experience. At launch, Keryx was ready with Veeva Commercial Cloud, including Veeva CRM, Veeva CRM Approved Email, and closed loop marketing (CLM); Veeva Vault PromoMats for promotional materials management; and Veeva Network customer master.
VEEV: 30.12 (+0.17), KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 6:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 33 Annual J.P. Morgan Healthcare Conference, being held January 12-15, at the Westin-St. Francis Hotel in San Francisco, California.
JPM: 59.67 (+0.10), KERX: 11.63 (-0.60)
InsiderInsights.com Daily Round Up 1/2/15: IFT, OPK, SNCR, GPRE
InsiderInsights - at Seeking Alpha - Mon Jan 05, 2:55AM CST
ATRC: 18.86 (+0.04), MAR: 79.39 (+0.37), SHLD: 35.70 (+2.32), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), WIW: 11.29 (unch), PLUS: 80.17 (-0.21), OCIP: 16.27 (-0.46), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), AFG: 62.89 (+0.08), CFNL: 19.32 (+0.02), GPRE: 25.50 (-0.56), BDN: 16.45 (-0.17), NMBL: 23.19 (+0.81), AAPL: 127.08 (+0.62), ALCO: 45.40 (+1.44), IFT: 6.41 (+0.04)
Insider Buys And Sells: Biglari Holdings, Graham Holdings
Asif Suria - at Seeking Alpha - Sun Jan 04, 8:55AM CST
Happy New Year and welcome to edition 237 of Insider Weekends. Insider buying declined last week with insiders buying $18.4 million of stock, compared to $83.07 million in the week prior. Selling also declined sharply with insiders selling $258.37...
BH: 416.41 (-1.55), OCIP: 16.27 (-0.46), SCTY: 57.60 (+0.44), JAZZ: 169.69 (+6.89), CFNL: 19.32 (+0.02), AMP: 137.81 (+0.24), GHC: 976.65 (+15.51), OAS: 16.84 (-0.03), SLCA: 29.82 (+1.25), KERX: 11.63 (-0.60)
Keryx Driven By Recent Auryxia Launch In The US
Biotech Thoughts - Seeking Alpha - Sat Jan 03, 9:38AM CST
Background: KERX's value is driven by its main compound, Auryxia (ferric citrate), which was launched in the US in late December 2014 for the control of phosphorus levels in chronic kidney disease (CKD) patients on dialysis. Auryxia is also...
KERX: 11.63 (-0.60)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Downtrend Call Working As Keryx Biopharmaceuticals Stock Falls 25.7% (KERX)
Comtex SmarTrend(R) - Mon Feb 09, 9:44AM CST
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on December 12th, 2014 at $14.65. In approximately 2 months, Keryx Biopharmaceuticals has returned 25.73% as of today's recent price of $10.88.
KERX: 11.63 (-0.60)
Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch
at The Street - Mon Feb 09, 7:36AM CST
Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.
KERX: 11.63 (-0.60)
Why Keryx Biopharmaceuticals Shares Plummeted 14% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 8:55AM CST
KERX data by YCharts What: Shares of Keryx Biopharmaceuticals , a biopharmaceutical company focused on developing treatments for renal diseases, plummeted 14% in January per data from S&P Capital IQ following a share issuance and a...
KERX: 11.63 (-0.60)
Shares of KERX Down 17.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 02, 9:25AM CST
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on December 12th, 2014 at $14.65. In approximately 2 months, Keryx Biopharmaceuticals has returned 17.34% as of today's recent price of $12.11.
KERX: 11.63 (-0.60)
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 3:10PM CST
Keryx (KERX) will be raising $110 million through the issuance of the shares with plans to invest the funds on the ongoing commercialization and development of Auryxia in the U.S.
ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30), KERX: 11.63 (-0.60), CELG: 115.88 (+0.16)
Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 7:31AM CST
Keryx Biopharmaceuticals saw a big move last session, as the company’s shares fell by nearly 7% on the day.
ALXN: 182.29 (+6.02), KERX: 11.63 (-0.60)
Keryx prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:27AM CST
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
GlobeNewswire - Wed Jan 21, 6:53PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares at $12.00 per share, for gross proceeds of $110 million. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia(TM) (ferric citrate) in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
JPM: 59.67 (+0.10), KERX: 11.63 (-0.60)
Keryx initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 3:11PM CST
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jan 20, 3:06PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that it has commenced a $100 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
JPM: 59.67 (+0.10), KERX: 11.63 (-0.60)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Dyadic Appoints Michael Tarnok As Chairman Of The Board Of Directors
PR Newswire - Mon Jan 12, 7:40AM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok as the company's Chairman of the Board of Directors. Mr. Tarnok will continue to serve on the company's audit and compensation committees. KERX: 11.63 (-0.60)
New chief at Keryx
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:36PM CST
KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals Announces Transition of Leadership
GlobeNewswire - Sun Jan 11, 9:00PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"
today announced it will be transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison. Mr. Bentsur has led Keryx for the past 5 years, culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia(TM) (ferric citrate). Mr. Madison joined Keryx in February 2014 as Chief Operating Officer to transition the Company from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the phosphate binder and iron deficiency anemia markets. Mr. Madison has been appointed President of Keryx and will work with Mr. Bentsur to ensure a successful leadership transition by the end of May, when Mr. Bentsur's contract expires. KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
Business Wire - Thu Jan 08, 6:01AM CST
In 2014, Keryx Biopharmaceuticals needed to quickly build a commercial foundation for product sales and marketing to support its first FDA-approved product, Auryxia(TM) (ferric citrate). Keryx required a best-of-breed solution that would enable business agility and continuous improvement, plus easily accommodate change and rapid growth. Keryx found it in Veeva Commercial Cloud - a single solution that brings together customer data, multichannel interactions, and compliant content for a fully orchestrated customer experience. At launch, Keryx was ready with Veeva Commercial Cloud, including Veeva CRM, Veeva CRM Approved Email, and closed loop marketing (CLM); Veeva Vault PromoMats for promotional materials management; and Veeva Network customer master.
VEEV: 30.12 (+0.17), KERX: 11.63 (-0.60)
Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 6:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 33 Annual J.P. Morgan Healthcare Conference, being held January 12-15, at the Westin-St. Francis Hotel in San Francisco, California.
JPM: 59.67 (+0.10), KERX: 11.63 (-0.60)
InsiderInsights.com Daily Round Up 1/2/15: IFT, OPK, SNCR, GPRE
InsiderInsights - at Seeking Alpha - Mon Jan 05, 2:55AM CST
ATRC: 18.86 (+0.04), MAR: 79.39 (+0.37), SHLD: 35.70 (+2.32), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), WIW: 11.29 (unch), PLUS: 80.17 (-0.21), OCIP: 16.27 (-0.46), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), AFG: 62.89 (+0.08), CFNL: 19.32 (+0.02), GPRE: 25.50 (-0.56), BDN: 16.45 (-0.17), NMBL: 23.19 (+0.81), AAPL: 127.08 (+0.62), ALCO: 45.40 (+1.44), IFT: 6.41 (+0.04)
Insider Buys And Sells: Biglari Holdings, Graham Holdings
Asif Suria - at Seeking Alpha - Sun Jan 04, 8:55AM CST
Happy New Year and welcome to edition 237 of Insider Weekends. Insider buying declined last week with insiders buying $18.4 million of stock, compared to $83.07 million in the week prior. Selling also declined sharply with insiders selling $258.37...
BH: 416.41 (-1.55), OCIP: 16.27 (-0.46), SCTY: 57.60 (+0.44), JAZZ: 169.69 (+6.89), CFNL: 19.32 (+0.02), AMP: 137.81 (+0.24), GHC: 976.65 (+15.51), OAS: 16.84 (-0.03), SLCA: 29.82 (+1.25), KERX: 11.63 (-0.60)
Keryx Driven By Recent Auryxia Launch In The US
Biotech Thoughts - Seeking Alpha - Sat Jan 03, 9:38AM CST
Background: KERX's value is driven by its main compound, Auryxia (ferric citrate), which was launched in the US in late December 2014 for the control of phosphorus levels in chronic kidney disease (CKD) patients on dialysis. Auryxia is also...
KERX: 11.63 (-0.60)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
